What AI says about Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals uses its targeted RNAi molecule platform, TRiM™, to silence disease-causing genes. The company is advancing plozasiran (formerly ARO-APOC3) in Phase 3 trials for severe hypertriglyceridemia, aiming to have 20 products in clinical trials or on the market by 2025.